ClinicalTrials.gg
Status unknownNCT04902079REPORT-CCMUpdated Jun 3, 2021

Observational and Prospective Registry on Cardiac Contractility Modulation (CCM) Therapy

An observational study in Heart Failure, Systolic, sponsored by Monaldi Hospital. Status unknown at 1 site in Italy. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-06-03.

Sponsored by Monaldi Hospital · Observational

The sponsor has not verified this record recently (last verified Jun 2021), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
20
Ages
18 Years to 90 Years
Sex
All
01

Study summary

Observational and perspective study with acute and chronic endpoint.

Read the detailed description

This registry includes patients who have undergone implantation of the cardiac contractility modulation device due to the presence of heart failure with reduced left ventricular systolic function and symptomatic despite optimal therapy, as indicated in the guidelines of the ESC of 2016 and the Expert Consensus Document of the ESC Heart Failure group published in May 2019 for to assess the benefits after the CCM device.

02

Conditions studied

  • Heart Failure, Systolic

Keywords

  • Heart Failure
  • Quality of Life
  • Cardiac Contractility Modulation
03

In context

Heart Failure, Systolic

230 studies on the registry are indexed under Heart Failure, Systolic; 51 are open to participants now.

This study's planned enrollment of 20 is below the median of 250 across 54 observational studies indexed under Heart Failure, Systolic.

Browse Heart Failure, Systolic studies →

Lead sponsor

Monaldi Hospital is the lead sponsor of 7 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients with standard indication to CardiaC Contractility Modulation (CCM) therapy device system implantation

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or non-pregnant female, aged 18 or older;
  • chronic heart failure with symptomatic left ventricular systolic function; ( class II-IVa) with or without device already implanted (for example AICD, pace-maker);
  • Appropriate and optimized medical therapy
  • Patient signed and dated form at enrollment;
  • > 1 year due to the absence of comorbidities that reduce the prognosis

Exclusion criteria

Exclusion Criteria:

  • absence of venous access available for implant;
  • to the interventional procedure of CCM device implant (for example presence of Mechanical tricuspid vale);
  • pregnant patients
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
20 participants (estimated)
Patient registry
No

Interventions

  • DeviceDevice for Cardiac Contractility Modulation Therapy (CCM)

    Evaluate the effect from CCM Therapy in HF population

06

What researchers measure

Primary outcomes

  1. Improvement Quality of Life

    Evaluatation of the impact on CCM Therapy on Quality of Life evaluated from the reduction of MLWHFQ score at FU post implant of CCM device compared to baseline

    Time frame: 12 months

  2. Functional Capacity

    Evaluation of the impact on CCM Therapy on Functional Capacity evaluated from the gain of distance traveled in the 6MWT at FU post implant of CCM device compared to baseline

    Time frame: 12 months

  3. Reduction of HF Hospitalizations and Emergency Ward accesses

    Reduction of HF Hospitalizations and Emergency Ward accesses at FU post implant of CCM device compared to number of HF hospitalization an Emergency Ward accesses collected 1 year before the implant of CCM therapy

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
  • Monaldi Hospital
    Naples, 80131, Italy
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2021 (actual). Primary completion is estimated for Jun 2022, 15 months after the start.

Of 27 observational studies under Heart Failure, Systolic, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 53. This study's planned 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2021
First posted
May 26, 2021
StartActual
Mar 8, 2021
Primary completionEst.
Jun 30, 2022
CompletionEst.
Dec 31, 2023
Last update
Jun 3, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04902079
Lead sponsor
Monaldi Hospital
Responsible party
Antonio D'Onofrio (Head of UOSD Elettrofisiologia Studio e Terapia delle Aritmie, Monaldi Hospital) — Principal investigator
First posted
May 26, 2021
Start date
Mar 8, 2021
Primary completion
Jun 30, 2022 (estimated)
Completion
Dec 31, 2023 (estimated)
Last update
Jun 3, 2021

Study contacts

Antonio D'Onofrio, MD
Contact
donofrionat1@gmail.com
337768956
Giuliano D'Alterio, MD
Contact
gdalterio@libero.it
3332785271
Antonio D'Onofrio, MD
study director · Ao dei Colli - Monaldi Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion